Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Socinski

Showing results (11-20 of 279) with videos related to

Pageof 28
Sort By:
Clinical Lung Cancer|April 17, 2004
Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapyMark A Socinski
Clinical Lung Cancer|December 9, 2003
Irinotecan in non-small-cell lung cancer: status of ongoing trialsMark A Socinski
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2009
Fibroblastic growth factor pathwayMark A Socinski
Clinical Advances in Hematology & Oncology : H&O|February 13, 2015
Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? The significant impact of chemotherapy in lung cancerMark A Socinski
Oncology (Williston Park, N.Y.)|September 6, 2011
ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime timeMark A Socinski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?Mark A Socinski
Clinical Lung Cancer|May 5, 2010
The emerging role of biomarkers in advanced non-small-cell lung cancerMark A Socinski
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Bevacizumab as first-line treatment for advanced non-small cell lung cancerMark A Socinski
Seminars in Oncology|July 15, 2005
Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experienceMark A Socinski
Clinical Advances in Hematology & Oncology : H&O|March 14, 2015
Highlights in NSCLC from the 2014 ASCO meetingMark A Socinski
Pageof 28

Showing results (11-20 of 279) with videos related to

Sort By:
Pageof 28
Clinical Lung Cancer|April 17, 2004
Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapyMark A Socinski
Clinical Lung Cancer|December 9, 2003
Irinotecan in non-small-cell lung cancer: status of ongoing trialsMark A Socinski
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2009
Fibroblastic growth factor pathwayMark A Socinski
Clinical Advances in Hematology & Oncology : H&O|February 13, 2015
Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? The significant impact of chemotherapy in lung cancerMark A Socinski
Oncology (Williston Park, N.Y.)|September 6, 2011
ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime timeMark A Socinski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?Mark A Socinski
Clinical Lung Cancer|May 5, 2010
The emerging role of biomarkers in advanced non-small-cell lung cancerMark A Socinski
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Bevacizumab as first-line treatment for advanced non-small cell lung cancerMark A Socinski
Seminars in Oncology|July 15, 2005
Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experienceMark A Socinski
Clinical Advances in Hematology & Oncology : H&O|March 14, 2015
Highlights in NSCLC from the 2014 ASCO meetingMark A Socinski
Pageof 28